Jakafi 20 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRR3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,677
Award facts
- Contract value 100% obligated
- $24,676.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $24,676.82 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Jakafi 20 mg tablets (60-count units). The award was issued on December 23, 2025, with an ultimate completion date of December 24, 2025, under a firm fixed-price contract type with no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) designated SPE2DR, which was awarded on November 13, 2025, as part of the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative—a $30.3 billion acquisition strategy establishing multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V prime contract carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The company's comprehensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables across multiple therapeutic categories. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated consistent performance across numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, positioning the company to fulfill the diverse and specialized pharmaceutical requirements supporting military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRR3?
SPE2DR26FCRR3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FCRR3 worth?
The government has obligated $24,677 on SPE2DR26FCRR3.
Is contract SPE2DR26FCRR3 an order under another contract?
Yes. SPE2DR26FCRR3 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRR3 competed?
The extent of competition for SPE2DR26FCRR3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award